LEGAL NOTICE

DISCLAIMER
This document has been prepared by Oryzon Genomics, S.A. exclusively for use during the presentation. Oryzon Genomics, S.A. does not assume liability for this document if it is used with a purpose other than the above. Certain of the industry and market data contained in this presentation come from Oryzon Genomics, S.A.’s own internal research and estimates based on the knowledge and experience of Oryzon Genomics, S.A.’s management in the market in which Oryzon Genomics, S.A. operates. While Oryzon Genomics, S.A.’s believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry or market data contained in this presentation. Certain information contained herein is based on Oryzon Genomics, S.A.’s management information and estimates and has not been reviewed by Oryzon Genomics, S.A.’s auditors. Recipients should not be placed undue reliance on this information. This information is provided to the recipients for informational purposes only and recipients must undertake their own investigation of Oryzon Genomics, S.A. The information provided herein is not to be relied upon in substitution for the recipient's own exercise of independent judgement with regard to the operations, financial condition and prospects of Oryzon Genomics, S.A. The information and any opinions or statements made in this document have not been verified by independent third parties; therefore, no express or implied warranty is made as to the impartiality, accuracy, completeness or correctness of the information or the opinions or statements expressed herein. Oryzon Genomics, S.A. does not assume liability of any kind, whether for negligence or any other reason, for any damage or loss arising from any use of this document or its contents. Neither this document nor any part of it constitutes a contract, nor may it be used for incorporation into or construction of any contract or agreement. Information in this document about the price at which securities issued by Oryzon Genomics, S.A. have been bought or sold in the past or about the yield on securities issued by Oryzon Genomics, S.A. cannot be relied upon as a guide to future performance.

IMPORTANT INFORMATION
This document does not constitute an offer or invitation to purchase or subscribe shares, in accordance with the provisions of Law 24/1988, of 28 July, on the Securities Market, Royal Decree-Law 5/2005, of 11 March, and/or Royal Decree 1310/2005, of 4 November, and its implementing regulations. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any other jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration.

FORWARD-LOOKING STATEMENTS
This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public. Forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of Oryzon Genomics, S.A. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof.
COMPANY HIGHLIGHTS

✓ MADX: ORY  A **publicly traded** company on the Spanish Stock Exchange (*)

✓ A **clinical stage** biopharmaceutical company developing innovative therapies in the field of Epigenetics

✓ A competitive **EPIGENETIC PLATFORM** validated scientifically and clinically

✓ Three therapeutic programs in LSD1 in development with multiple indication opportunities

  ✓ In CNS  →  in 3 Phase IIAs

  ✓ in Oncology  →  in 2 Phase IIAs

  ✓ In an orphan disease  →  ready to start Phase I

✓ Large IP portfolio with technology fully developed in-house

---------------------------------------------

✓ **Raised €32M** in 2015-2016. Additional **€18.2M** raised from blue chip investors in the US and Europe **in March 2017**

✓ 34.1M Shares outstanding. Fully diluted.

✓ Loss/Earnings from Operations 1H2018: **-€1.5M**

✓ **Cash runway** expected till **1Q2020**

✓ One of the most **liquid** companies in the MicroCap group in the Spanish Stock Market


  ✓ +72M shares negotiated in 2018

---

**BOLSA DE MADRID**

ORYZON GENOMICS SA

BALANCE SHEET DATA (AUDITED)

(Amounts in thousands US $)

<table>
<thead>
<tr>
<th></th>
<th>June 30th, 2018</th>
<th>June 30th, 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>30,986</td>
<td>41,493</td>
</tr>
<tr>
<td>Marketable securities</td>
<td>165</td>
<td>1,303</td>
</tr>
<tr>
<td>Total Assets</td>
<td>68,352</td>
<td>70,932</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Total Stockholders' equity</td>
<td>40,697</td>
<td>41,972</td>
</tr>
</tbody>
</table>

---

(*) **€26.579 M. Audited by Deloitte**

* Spanish Automated Quotation System (Continuous Market) that includes Madrid, Barcelona, Bilbao and Valencia Stock Exchanges*
ORYZON: A UNIQUE COMPANY

**EPIGENETICS**
- One of the global leaders in Epigenetics with an efficient platform
- Highly specialized in LSD1, one of the most promising targets in the field (GSK, Takeda, Celgene, Incyte, etc.)
- Leading the field in clinics and exploring a variety of development possibilities

**BROAD PRODUCT PIPELINE**
- World class science and a broad patent portfolio
- A diverse and promising Pipeline: 2 Programs in Clinic and another ready to start
- 5 trials in Phase IIa. Additional indications under exploration. Strong science-driven decisions to position our drugs in clinical trials
- A Program in CNS with a strong transformation potential

**PROVEN TRACK RECORD**
- Skilled & Resilient team in a highly capital efficient company (~€50m raised in equity since inception)
- First ever University Start-Up to become public in Spain
- A leading licensing deal signed in Spain by a Biotech (ROCHE $21m Upfront).

**SOLID SITUATION**
- Expected Cash Runway beginning of 2020
- Compact Human team
- Clinical Programs approved and launched

**INVESTMENT PROPOSAL**
- Company is at an important inflection point and will consider a potential Dual Listing in Nasdaq in the future
- Rich flow of catalysts in 9-12m
- Currently undervalued compared with its natural peers
Lysine specific histone demethylase 1 (LSD1), also known as KDM1A, removes methyl marks at mono- and dimethyl-H3K4 (histone H3 lysine 4) and H3K9 (histone H3 lysine 9)

“Erasing” methyl marks (demethylation) regulates the expression of genes that are important in the onset and progression of certain diseases as cancers and others

Aberrant expression of LSD1 has been shown in many types of cancers, such as bladder, SCLC, colorectal, AML, ALL, some breast cancers, prostate and aggressive brain cancers

LSD1 plays a very important role in the development and function of the CNS

LSD1 Overexpression Leads to:
- Hematopoietic differentiation
- Neuron differentiation
- Tumorigenesis in Leukemia and Solid Tumors
### EXTENSIVE PIPELINE: 2 PROGRAMS IN CLINIC WITH MULTIPLE INDICATIONS

- **A Productive Epigenetic Platform**
- **A strong focus on LSD1**
- **3 Different LSD1 inhibitors in development**
- **Additional programs on other targets**

#### VAFIDEMSTAT (ORY-2001) - dual LSD1-MAO B inhibitor
- Alzheimer's disease (Mild Moderate)
- Multiple Sclerosis (Relapse Remitting & Secondary Progressive)
- CNS Basket Trial
- Aggression REIMAGINE monotherapy *(2)*

#### IADADEMSTAT (ORY-1001) - selective LSD1 inhibitor
- AML (Elderly Unfit)
- SCLC (First Line Relapsed)
- ALICE Combo w Aza *(2)*
- CLEPSIDRA Combo w Platinum/Etoposide *(3)*

#### ORY-3001 - selective LSD1 inhibitor
- Non Oncological
- Preclinical finished

#### OTHER PROGRAMS
- Undisclosed

---

*(1) Approved. Recruitment ongoing
(2) Approved
(3) CTA submitted*
Solid evidence of an Epigenetic axis in CNS diseases

In neurodegenerative disorders

- Historic results with HDACi’s
  - HDACi improves HD symptoms in animal models
  - HDAC2 inhibition recovers memory on the AD bi-tg CK-p25 Tg mouse model
  - HDAC inhibition improves FTD
  - HDAC inhibition improves MS in EAE models


In Psychiatric disorders

- HDAC inhibition suggested also to work in Major depression
- Histone methylation is also implicated in depression.
Epigenetics MoA in CNS is often exercised through transcription control

- Most of the Epigenetics enzymes have a dual role:
  - Enzymatic → As Chromatin remodelers
  - Scaffolding → Interacting with a variety of Transcription Factors and other epigenetic modulators through protein-protein interactions that results in Transcriptional Complexes and super-enhancers controlling the expression of key genes for cellular function (see example below)

- HDACs are difficult targets for chronic use in non-life threatening diseases:
  - The different HDACs are quite pleiotropic → Many signaling pathways will always be affected
  - The different HDACs are highly conserved → So far it has been impossible to produce real selective inhibitors

- LSD1 is a key component of different CNS Transcriptional complexes interacting with different Transcription Factors and very often with HDAC1 and HDAC2
  - LSD1 is not a very pleitropic target
  - Different to what happens in HDACs, it has been proven that it is possible to develop extremely selective LSD1 inhibitors with excellent pharmacological properties
VAFIDEMSTAT (ORY-2001)

A new experimental drug for the global treatment of Neurodegenerative and Psychiatric Disorders

VAFIDEMSTAT acts in a holistic way on the different domains that are presented in human CNS indications

Leading Epigenetic therapies in CNS
VAFIDEMSTAT (ORY-2001), a “NEURON-FIXER”. Summary

- A small molecule that selectively inhibits LSD1 and MAO-B
- Excellent Pharmacology.
- Safe in 6 and 9 months PC regulatory toxicological studies.
- Positive results in many different animal models and in many in-vitro models:
  - Cognition: Improves cognition in SAMP8 AD model and in R6/1 HD model
  - Locomotion: Improves locomotion and motility signals in the EAE and Thyler’s MS models and in the R6/1 HD model
  - Neuroprotection: Produces axonal protection in the Thyler’s MS model, and in IV glutamate excitotoxic challenging
  - Neuroinflammation: Reduces neuroinflammation in SAMP8 AD model and in the EAE and Thyler’s MS models
  - Social Withdrawal / Apathy: Reverts social avoidance in the rat isolation model, increases sociability in the TCT in the SAMP8 AD model
  - Aggression/Agitation: Reverts severe aggressiveness in SAMP8 AD model
  - Others: Protection in the rat OH-dopamine and mouse MPTP challenges
- MoA: Reset the Gene expression program → Strong anti-neuroinflammatory activity and enhances synaptic plasticity
- Biomarkers identified in animals that show promise for use in human clinics
- Capable of acting in all the processes that manifest in neurodegenerative disease patients
- Safe in humans in a Phase I trial. Oral once daily
- Crosses the BBB and engages the target in humans

In Phase IIa (in MS, AD and in a basket trial in aggression)
LSD1i activity is the driving effector in Vafidemstat. MAO-B component is a synergizing-or-helper component.

Capable of acting in most of the processes that manifest in patients with different neurodegenerative and psychiatric diseases.

<table>
<thead>
<tr>
<th>ORY-2001 Results in PC models</th>
<th>Neurodegenerative space</th>
<th>Psychiatric space</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AD</td>
<td>MS</td>
</tr>
<tr>
<td>Cognition / Memory</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Neuroprotection</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Neuroinflammation</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Social Withdrawal / Apathy</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Sociability</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aggression/Agitation</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

These data may sustain a broader clinical development of ORY-2001 beyond the current indications of AD and MS.
VAFIDEMSTAT (ORY-2001)

An epigenetic drug that enhances neuronal recovery allowing a broad clinical development

CLINICAL DEVELOPMENT
VAFIDEMSTAT (ORY-2001) Phase I: Safety and hematology

- Safe and well tolerated in the conditions tested in +100 healthy volunteers

- ORY-2001 efficiently crosses the BBB:
  - ORY-2001 concentrations measured in CSF at 2, 6 and 12 h after a single oral 2 mg or 4 mg dose
  - CSF levels comparable to corresponding unbound plasma concentrations (CSF/plasma ratio ≈ 0.7-0.9)

- ORY-2001 efficiently inhibits the brain human LSD1

  - **PK** Oral PK $T_{1/2} \approx 22$ h allowing once daily oral

  - **PK/PD** data allow to select Phase II doses

VAFIDEMSTAT (ORY-2001) is in Phase II in humans in AD and MS where we expect to have the first read outs in 2H-2019
Mild to Moderate patients
Nº of patients: 150
Primary Objective: SAFETY & Tolerability
Secondary Objectives:
  - Cognition/Agitation/Apathy/QoL
  - CSF Biomarkers
  - Volumetric MRI

125 in EU, 17 sites
Actively recruiting in SP, UK and FR

A Twin study in US: around 25 patients
IND submission October
IND expected approval November
FPI expected 1Q2019

Already approved in Spain, France and UK
First Patients enrolled in May
Why a study in Mild and Moderate AD patients?

- **VAFIDEMSTAT (ORY-2001)** fully restores cognition to normal levels in SAMP8 AD model
- Changes Behavior in various models
  - Reverts Aggressiveness
  - Reverts social withdrawal
  - Enhances sociability
- Easier to recruit patient target population

Preclinical results suggestive of Disease modifying potential
VAFIDEMSTAT (ORY-2001) reduces aggression in mice Alzheimer’s Disease model

Following unplanned observations that SAMP8 male mice treated with ORY-2001 (bottom mouse) presented a better condition than untreated animals (top mouse) suggesting that ORY-2001 might reduce the aggressions between males caged together. Later we confirmed this in proper Resident-intruder aggression tests.
**ETHERAL: Epigenetic THERapy in ALzheimer’s Disease**

**Expected First Clinical read outs in mid-2019**

- **MMSE**: 16-26
- **CSF analysis**: Abeta+ P-Tau+
- **Randomization**: MRI at baseline Cogstate at baseline

**1.2 mg ORY-2001**
- MRI at 6 months
- Cogstate at 6 months
- Cognition at 6 months
- Behaviour at 6 months
- Biomarkers at 6 months

**0.6 mg ORY-2001**
- MRI at 6 months
- Cogstate at 6 months
- Cognition at 6 months
- Behaviour at 6 months
- Biomarkers at 6 months

**placebo**
- MRI at 6 months
- Cogstate at 6 months
- Cognition at 6 months
- Behaviour at 6 months
- Biomarkers at 6 months

**+6 months**

**Interim Report**

- Feb
- Mar
- Apr
- May
- Jun
- Jul
- Aug
- Sep
- Oct
- Nov
- Dec

**2019**

AAIC 19

FA D

ORYZON
S100A9 was one of the TOP10 up-regulated genes in LOAD dataset

- S100A9 PROTEIN levels are significantly increased in CSF from AD patients compared to age-matched controls
- S100A9 CSF PROTEIN levels will be monitored in ETHERAL AD trial
  - S100A9 and inflammation have a correlation with the disease
  - Inflammation plays a mechanistic role in the progression of the disease
  - ORY-2001 reduces S100A9 in animals

Will it be accepted by regulatory agencies as a surrogate for activity? May it be the basis for a fast track?

Changes in S100A9 in patient’s CSF may have important clinical development implications
SATEEN  A pilot study in MS

SAfety, Tolerability and Efficacy in an EPIGENETIC approach to treat Multiple Sclerosis

Randomised, double-blind, placebo-controlled, 3-arm, 36 weeks parallel-group study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS)

APPROVED by the AEMPS in 4Q-2017

Spain only; 8 Hospitals; 24 patients (RR & SP);

FPI January 2018

expected LPO 2H-2019
VAFIDEMSTAT strongly reduced neuro-inflammation in a fast manner in various MS models.

The effect is long-lasting after treatment.

The effect is stronger and faster than Fingolimod (Gilenya®, Novartis).

The MoA has similitudes with Fingolimod but has differential hallmarks.

Results are suggestive of neuro-protection in the Thyler’s MS model (increased axonal protection).

Why did we start a trial in RR and SP MS with VAFIDEMSTAT (ORY-2001)?
Primary objective:
✓ Evaluate safety - tolerability of 2 ORY-2001 doses compared to placebo.

Secondary objective:
✓ Assess effect of 2 ORY-2001 doses on MRI measures compared to placebo.

Exploratory objectives:
✓ Assess effect of 2 ORY-2001 doses on focal tissue damage MRI measures compared to placebo.
✓ Assess effect of 2 ORY-2001 doses on diffuse tissue damage MRI measures compared to placebo.
✓ Assess effect of 2 ORY-2001 doses on inflammation MRI measures compared to placebo.
✓ Assess effect of 2 ORY-2001 doses on Optical Coherence Tomography (OCT) derived measures compared to placebo.
✓ Assess the effect of 2 ORY-2001 doses on body fluid biomarkers of tissue damage compared to placebo. LSD1 Target Engagement (TE), Plasma Neurofilament Light Chain (NLC) and Th1/Th2 cytokines (IL2, IFNγ, IL4 and IL10) in serum.
VAFIDEMSTAT (ORY-2001) in Psychiatric disorders:

Produces profound changes in animal behavior

VAFIDEMSTAT reduces aggression, enhances sociability and diminishes social withdrawal

Leading Epigenetic therapies in CNS
ORY-2001 REIMAGINE Study

- An open label exploratory basket trial to assess the effect of ORY-2001 in reducing aggression in patients with the following neurodegenerative or neuropsychiatric diseases:
  - AD
  - DLB
  - ADHD
  - ASD
  - BPD

- 6 patients per indication. 8 weeks of treatment
- Single arm of ORY-2001 (1.2 mg)
- No placebo control. 1 single site
- FPI 2H2018
- Expected LPO 1Q2019

CTA approved by AEMPS
IADADEMSTAT
(ORY-1001)
LSD1 inhibitors in Cancer
SUMMARY
ORYZON LSD1 inhibitors are a potential therapeutic approach for Acute Leukemias

LSD1 is a target for HEMATOLOGICAL CANCERS, and in particular, for a subset of acute myeloid leukemia: *mixed lineage leukemia* MLL-AML

- Oryzon’s LSD1 inhibitors block progression of leukemia into the circulation in mice with experimentally initiated MLL-AF9 AML

- Oryzon’s LSD1 inhibitors target Leukemia Stem Cells but spare normal HSPCs
ORYZON LSD1 inhibitors are a potential therapeutic approach for Acute Leukemias

ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia

Tamara Maes,1,6,6 Cristina Mascaró,1 Iñigo Tirapu,1 Angels Estiarte,1 Filippo Ciceri,1 Serena Lunardi,1 Nathalie Guibourt,1 Alvaro Perdones,1 Michele M.P. Lufino,1 Tim C.P. Somerville,2 Dan H. Wiseman,2 Cihangir Duy,2 Ari Melnick,3,4 Christophe Willekens,2 Alberto Ortega,1 Marc Martinell,1 Nuria Valls,1 Guido Kurz,1 Matthew Fyfe,1 Julio Cesar Castro-Palomino,1 and Carlos Buesa1

1Oryzon Genomics, S.A., Carrer Sant Ferran 74, 08940 Cornellà de Llobregat, Spain
2Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK
3Department of Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine, New York, 10065 NY, USA
4Department of Pharmacy, Weill Cornell Medicine, New York, 10065 NY, USA
5Drug Development Department (DITEP) and Hematology Department, Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France
6Lead Contact
*Correspondence: tmaes@oryzon.com
https://doi.org/10.1016/j.ccell.2018.02.002

ORY-1001: Overcoming the Differentiation Block in AML

Prithviraj Bose1 and Marina Y. Konopleva1,2
1Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2Correspondence: mkonoplev@mdanderson.org
https://doi.org/10.1016/j.ccell.2018.02.014

In this issue of Cancer Cell, Maes and colleagues report in vitro and in vivo findings with ORY-1001—an oral, highly potent and selective covalent small-molecule inhibitor of lysine-specific demethylase 1 (LSD1)—in development for acute myeloid leukemia (AML), as well as correlative data from two AML patients receiving ORY-1001.
LSD1 inhibitors are a potential therapeutic approach for IO combos

**Cell**

**LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade**

Graphical Abstract

**Authors**
Wangqiang Sheng, Martin W. LaFlour, Thao H. Nguyen, ..., Housheng Hansen He, Arlene H. Sharpe, Yang Shi

**Correspondence**
arlene.sharpe@hms.harvard.edu
yang.shi@hms.harvard.edu

**In Brief**
Ablating the histone demethylase LSD1 genetically or pharmacologically enhances tumor immunogenicity by stimulating endogenous retrovirus expression and downregulating RNA-induced silencing complex, supporting the promise of LSD1 inhibition in overcoming resistance to checkpoint blockade in cancer treatment.

**Highlights**
- ERV induction and RISC reduction activate dsRNA-IFN pathway upon LSD1 inhibition
- LSD1 loss in tumor cells stimulates anti-tumor T cell immunity
- LSD1 ablation enhances tumor immunogenicity and T cell infiltration
- LSD1 inhibition overcomes resistance to anti-PD-1 therapy in a mouse melanoma model

**Data resources**
GSE112230

(A and B) Tumor growth (A) and survival curves (B) of immunocompetent mice inoculated with 250 k B16 melanoma cells, and treated with anti-PD-1 or isotype control. Arrows indicate time points of anti-PD-1 injection.
IADademstat (ORY-1001) PHASE I/IIa in Acute Leukemia relapsed-refractory patients:

- Manuscript under preparation.

- Iadademstat (ORY-1001) was administered to **41 patients**

- **Excellent oral bioavailability** in humans and excellent PK parameters

- **Pharmacodynamic biomarkers (MLLr)** permit monitoring response to iadademstat (ORY-1001) in M4/M5 AML patients

- **22% (6/27) response rate in the dose finding part of phase 1, including one CRi** (complete remission with incomplete blood count recovery)

- **46% (6/13) of relapsed/refractory AML patients showed anti-leukemic clinical activity** in the extension arm (Phase IIa)

- Partial bone marrow remission in 50% (2/4) M6 patients, **suggesting disease stabilization**

- 100% (5/5) of MLL gene fusion patients with evaluable PD samples showed evidence of blast differentiation by qRT-PCR analysis

- 67% (4/6) of MLL leukemia patients showed evidence of morphological blast cell differentiation (2 patients experienced a differentiation syndrome)

- 15% (2 (M6)/13) partial bone marrow responses and 1 MLL patient with 3 month hematologic improvement

- **From all patients in the Phase I/IIa study, antileukemic activity observed in 29% of patients (12/41), including one CRi**
ALICE: An AML trial with LSD1 in Combination with azacitidine in the Elderly

A Phase IIa study to evaluate safety, tolerability, dose finding and efficacy of IADADEMSTAT (ORY-1001) in combination with azacitidine in older patients with AML in first line therapy.

36 patients. Open label.
2 sites in Spain
The study is organized in two parts.

The objective of Part 1 is to determine the recommended doses of ORY-1001 in elderly unfit AML patients
The objective of Part 2 is to evaluate the clinical activity of ORY-1001 in first line elderly unfit AML patients in combination with Azacitidine

Primary end point: safety
Secondary endpoints: responses; time to responses; duration of response; and overall survival

Expected Clinical Study Time Frame:
First patient in: 3Q 2018
Last patient first visit: 3Q 2019
Last patient last visit: 3Q 2020
Clinical Study Report: 4Q 2020

CTA approved by AEMPS
CLEPSIDRA: A Combination trial of LSD1 and Etop-Platinum in Small Cell Lung Cancer in Biomarker-ID Relapsed Patients

A Phase IIa study to assess the safety, tolerability, dose finding and efficacy of Iadademstat (ORY-1001) in combination with platinum-etoposide chemotherapy in patients with relapsed, extensive-stage disease small cell lung cancer.

36 patients (1). Open label.

4 sites in Spain

The study is organized in two parts.

The objective of Part 1 is to determine the recommended doses of ORY-1001 in combination with platinum–etoposide chemotherapy.

The objective of Part 2 is to evaluate clinical activity of ORY-1001 in combination with platinum–etoposide chemotherapy.

Primary end point: safety

Secondary endpoints: RECIST responses; time to responses; duration of response; and overall survival

Expected Clinical Study Time Frame:
- First patient in: 4Q 2018
- Last patient first visit: 4Q 2019
- Last patient last visit: 4Q 2020
- Clinical Study Report: 1Q 2021

CTA requested to AEMPS in July 2018

(1) Relapsed but platinum sensitive, extensive-stage disease small cell lung cancer who are positive to candidate predictive biomarkers.
Regain of full control of IADADEMSTAT (ORY-1001)

Phase IIa CTA/IND filed for Hematol. Cancer
Phase IIa CTA/IND filed for SCLC

2018

SATEEN
FPI in a Phase IIa study in MS
ETHERAL
FPI in a Phase IIa study in AD

1Q
2Q
3Q
4Q

2019

ALICE
CLEPSIDRA

Phase IIa FPI in Hematol. Cancer
Phase IIa FPI in SCLC

Period of Preliminary Clinical Read Outs

Anticipated FPI in a Basket trial in Aggression
Basket trial Prelim read outs
Phase IIa Prelim read outs in MS
Phase IIa Prelim read outs in AD

VAFIDEMSTAT (ORY-2001): lead CNS asset

ORYZON
ORYZON: A Unique Case

- One of the global leaders in Epigenetics with an efficient platform
- Highly specialized in LSD1, one of the hottest targets in the field (GSK, Takeda, Celgene, Incyte, ...)
- World class science and a broad patent portfolio
- A diverse and promising Pipeline
- Public in Europe with an experienced management and BoD
- Robustly financed
- Catalysts in 9-12m
- Currently undervalued compared with its natural peers
- Dual Listing in Nasdaq expected in the future
ORYZON
A GLOBAL LEADER IN EPIGENETICS

CARLOS BUESA
CEO & President
cbuesa@oryzon.com

TAMARA MAES
CSO
tmaes@oryzon.com

ROGER BULLOCK
CMO
rbullock@oryzon.com

EMILI TORRELL
BDO
etorrell@oryzon.com